Scilex Holding (SCLXW) Free Cash Flow (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Free Cash Flow of $900000.0 in Q1 2026, up 105.15% quarter-over-quarter from -$17.5 million in Q4 2025, and down 85.02% on a YoY basis from $6.0 million in Q1 2025.
Scilex Holding (SCLXW) Free Cash Flow (2020 - 2026) Analysis & Trends
Scilex Holding's Free Cash Flow history runs 7 years deep, the most recent figure standing at $900000.0 for Q1 2026.
- In Q1 2026, Free Cash Flow fell 85.02% year-over-year to $900000.0; the TTM figure through Mar 2026 stood at -$1.3 million (down 108.09% YoY), while the FY2025 annual figure was $3.7 million, down 80.97% from the prior year.
- Free Cash Flow was $900000.0 for Q1 2026 at Scilex Holding, up from -$17.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $9.4 million in Q1 2024 to a low of -$17.5 million in Q4 2025.
- Historically, Free Cash Flow has averaged -$1.1 million across 5 years, with a median of $2.3 million in 2024.
- Biggest YoY gain for Free Cash Flow was 1879.14% in 2022; the steepest drop was 2136.1% in 2022.
- A 5-year view of Free Cash Flow shows it stood at -$725000.0 in 2022, then plunged by 643.59% to -$5.4 million in 2023, then soared by 147.0% to $2.5 million in 2024, then plunged by 789.46% to -$17.5 million in 2025, then surged by 105.15% to $900000.0 in 2026.
- The last three Free Cash Flow figures came in at $900000.0 (Q1 2026), -$17.5 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.12 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 900,000.00 |
| Mar 31, 2026 | 900,000.00 |
| Dec 31, 2025 | -17.47 Mn |
| Dec 31, 2025 | -17.47 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 7.09 Mn |
| Jun 30, 2025 | 7.09 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Dec 31, 2023 | -5.39 Mn |
| Dec 31, 2023 | -5.39 Mn |